Business
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio.
About this update from Armata Pharmaceuticals, Inc.
[{"type":"text","content":"Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 ","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio.","length":457,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TDyYNi5HXQc0YIMWA0R4MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMQ--/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail, AP-PA02. Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections due to Pseudomonas aeruginosa in people with cystic fibrosis (CF) and with non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 has shown promising results in two Phase 2 clinical trials to date, SWARM-P.a. (NCT04596319) and Tailwind (NCT05616221). Armata remains focused on proving the clinical utility of phages as well as conducting bench science to deepen the knowledge of phage mechanism of action.","length":731,"tagName":"p"},{"type":"text","content":""Understanding the structure of our phages is an important element of our development strategy, including life cycle management of our clinical product candidates," stated Dr. De...